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perspective, more research is needed to identify the reasons for augmentation in chil-
dren and adolescents with ADHD (e.g., duration of effect, titration) and to examine 
patterns of medication taking throughout the day.
PMH86
CONTINUITY OF CARE FOLLOWING HOSPITALIZATION FOR
BIPOLAR DISORDER IN PRIVATE PAYER CLAIMS
Stensland MD1, Peng X2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Poor continuity of care occurs when patients do not follow-up after 
being discharged from the hospital. In bipolar disorder problems with continuity of 
care and medication adherence may lead to expensive relapses. The objectives of this
research were threefold: 1) examine the frequency of poor continuity of care for indi-
viduals with bipolar disorder; 2) identify the predictors of poor continuity of care; 
and 3) evaluate the potential increased psychiatric hospitalization costs. METHODS:
Premier linked their PerspectiveTM Comparative Database (PCD), the largest, most
detailed, U.S. hospital database, with the administrative claims from a large managed 
care organization. We identiﬁ ed 319 individuals who had a primary discharge diag-
nosis of bipolar disorder in the PCD and who maintained continuous eligibility for
the 60 days prior and the 180 days following the hospitalization. Good continuity of 
care was operationally deﬁ ned as the presence of a psychiatric visit in the 60 days 
following discharge. Propensity scores were used to correct for background differences
between patients with good continuity of care and patients with poor continuity of 
care. RESULTS: A total of 34.5% of individuals had poor continuity of care. Prior to
discharge, individuals who would later have poor continuity of care could be identi-
ﬁ ed. Some variables that independently predicted later poor continuity of care included
no psychotherapy visits, no psychiatric visits, substance use diagnoses, and psychiatric
hospitalizations. After correcting for background differences, patients with poor con-
tinuity of care had reduced mood stabilizer use (94 vs. 116 days, p  0.008) and twice 
the psychiatric hospitalization charges ($10,027 vs. $4,892, p  0.03). CONCLU-
SIONS: One in three individuals with bipolar disorder did not have a psychiatric 
follow-up visit after discharge from the hospital. This poor continuity of care appears
to lead to decreased medication adherence and increased psychiatric hospitalizations.
An effective, targeted intervention could potentially prevent relapses and reduce health 
care costs.
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TREATMENT PATTERNS BY RACE/ETHNICITY AND INCOME LEVELS
AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 
SUBJECTS TREATED WITH SHORT-, INTERMEDIATE-AND LONG-ACTING
STIMULANTS
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
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OBJECTIVES: This research examines the relationship of ethnicity and income with 
attention-deﬁ cit hyperactivity disorder (ADHD) treatment patterns among subjects on 
medications of different durations. METHODS: Claims of newly treated ADHD sub-
jects, aged q6 years, initially treated with stimulants, and continuously enrolled in a
US commercial health plan 6 months prior and 12 months after their ﬁ rst prescription 
(January 1, 2004 “C September 30, 2006) were studied. Subjects took short- (SAS)
intermediate- (IAS) or long-acting (LAS) stimulant medication for ADHD. Persistence 
was deﬁ ned as the number of days on initial therapy. Adherence was deﬁ ned as the 
number of days of initial therapy divided by persistent days. Differences in mean per-
sistence and adherence, dosing, switching and augmentation among ethnicities (non-
Hispanic Caucasians [NHC], Hispanics [H] and African Americans [AA]) and among 
income levels were assessed. RESULTS: Among children on LAS (n  12,796), NHC 
had the highest mean adherence (0.56) and the longest mean persistence (251 days) 
(p  0.0001 among groups), while AA had the shortest persistence (222 days) and the
lowest adherence (0.46) (p  0.0001 among groups). Similarly, among adults receiving 
LAS (n  8422), NHC had the highest adherence (0.58) and the longest persistence 
(225 days). Persistence was again shortest among AA (194 days; p  0.037 among 
groups), while adherence was equally low for AA and H (0.52; p  0.002 among 
groups). Within treatment groups of different durations, the propensity of subjects to 
change dose, switch or augment their medication varied according to ethnicity. While 
no signiﬁ cant relationship between race/ethnicity and either adherence or persistence 
was found among children or adults receiving SAS or IAS, the IAS and LAS groups 
showed greater persistence and adherence with increased income levels in some sub-
jects. CONCLUSIONS: Persistence and adherence to stimulant medications differed 
by race/ethnicity and income. This may have implications for the optimal management
of ADHD.
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A SYSTEMATIC EVALUATION OF PUBLISHED LITERATURE TO ASSESS 
BURDEN OF TREATMENT-RESISTANT DEPRESSION
Cyr P1, Bockstedt L2, Olchanski N1, Halseth M2, Partlow K3, Lindeke C2, Handke B2, 
Goss T3
1Boston Healthcare Associates, Inc, Boston, MA, USA, 2Medtronic Neuromodulation, Fridley, 
MN, USA, 3Boston Healthcare Associates, Inc, Washington, DC, USA
BACKGROUND: Treatment-resistant depression (TRD) is severely disabling with no
treatments proven to provide sustainable beneﬁ t when multiple medications, psycho-
therapy, and electroconvulsive therapy fail. (Malone, 2008). OBJECTIVES: The 
perform a systematic review of published literature to evaluate recent health economics
and outcomes research related to TRD to inform future research initiatives. 
METHODS: English language citations in PubMed and Cochrane Library from 
January 1, 2000–October 1, 2008 were systematically reviewed. Standard search terms
deﬁ ned disease states (including TRD, severe depression (SD), chronic depression
(CD), major depressive disorders (MDD), and suicidality); interventions (deep brain
stimulation, electroconvulsive therapy, transcranial magnetic stimulation and vagus
nerve stimulation); and outcomes (treatment outcomes, presenteeism, symptom
burden, resource utilization, productivity, cost, economics, and quality of life(QOL)). 
RESULTS: Initial searches yielded 8811 citations, narrowed to 5626 using date and 
language criteria. Title review further narrowed literature (reasons: not related to 
depression ^70%, clinical trials of antidepressant medications ^20%, and review/case 
studies ^10%), resulting in 411 unique abstracts for review and forty publications for 
abstraction. Clinical studies were most frequent (n  16) and economic models least 
frequent (n  3); a majority (n  22) reported a U.S. patient population. Thirteen 
publications reported on TRD, thirteen on MDD, and six reported on a “general 
depression” population. Reported deﬁ nitions of TRD varied greatly (one medication
failure (n  2), two medication failures (n  6), HAM-D score (n  3), diagnosis/treat-
ment algorithm (n  1), not deﬁ ned (n  1)). HAM-D (n  12) and MADRS (n  9) 
were the most frequently reported clinical outcomes measures. Cost outcomes were 
discussed in thirteen reports (direct costs (n  11), indirect costs (n  2)). CONCLU-
SIONS: Deﬁ nitions of TRD or CD reported in the literature vary substantially, and 
studies examining productivity of patients were conﬁ ned to generic depression or
MDD populations and would not be directly comparable to a CD or TRD population. 
Additional research is necessary to better deﬁ ne the cost and patient burden of 
TRD.
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
PREVALENCE OF INSOMNIA IN EUROPE: A COMPARISON OF FIVE
COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess the prevalence of insomnia among ﬁ ve large European 
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24,25–34,35–44,45–54,55–64,65–69yrs) strata 
in respective countries, ensured by sampling and intensive panel management. The
survey collected information on select health conditions (incl. insomnia/sleeping-
problems; in the past 12-months), quality of life and health care-utilization. RESULTS:
Total of over 160,000 adult individuals in the European Healthcare Panel com-
pleted survey in the ﬁ ve European nations. Prevalence of Insomnia varied widely
between these 5 nations, as follows (All, Male, Female, % individuals): Netherlands:
13.5%,9.2%,18.0%; Italy: 18.5%,13.3%,23.6%; U.K: 19.3%,14.7%,24.0%;
Germany: 21.6%,16.2%,27.0%; France: 27.6%,19.9%,35.0%. Within each country, 
burden of Insomnia varied by age and gender; distribution among male (18–24,
25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands: 6.4%,8.5%,8.1%,
10.9%,11.0%,8.9%; Italy: 11.1%,8.9%,12.6%,15.7%,16.1%,18.9%; U.K: 9.8%,
10.8%,16.6%,18.1%,17.0%,12.9%; Germany: 12.8%,14.1%,17.1%,19.6%,18.0%,
11.6%; France: 15.9%,17.8%,21.2%,24.0%,19.5%,18.9%; distribution among 
female (18–24,25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands:
8.5%,12.5%,15.5%,23.7%,23.4%,25.6%; Italy: 16.9%,19.1%,22.4%,28.0%,
27.2%,27.2%; U.K: 17.1%,18.2%,23.0%,30.1%,30.0%,24.8%; Germany: 23.3%,
23.5%,26.5%,32.0%,27.6%,26.2%; France: 28.5%,29.6%,34.2%,39.9%,40.3%,
37.2%. General Practitioners were the primary point of diagnosis and source of treat-
ment, even though this statistic varied between the countries. CONCLUSIONS: Preva-
lence of insomnia appears to be substantial in the studied European nations, with 
France bearing the most burden (one-in-ﬁ ve and one-in-three males and females
respectively in France suffered from this condition). Prevalence peaked among the 
45–64 age-group across the countries. Females had substantially higher disease burden
across the countries, amounting to as much as 1.5 to 2 times more than their male
counterparts in certain age groups.
PND2
CHRONIC MIGRAINE CRITERIA AND THEIR EFFECTS ON GLOBAL
PREVALENCE ESTIMATES: A SYSTEMATIC REVIEW
Natoli JL1, Manack A2, Dean BB1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Allergan, Inc., Irvine, CA, USA
OBJECTIVES: The deﬁ nition of chronic migraine (CM), as opposed to episodic 
migraine, has evolved over 20 years of clinical study. This systematic review summa-
rized population-based studies reporting CM prevalence and examined how variations 
in deﬁ nitions affected estimates. METHODS: We conducted a systematic search 
of PubMed, Cochrane, and EMBASE. Search terms included chronic migraine, 
transformed migraine, chronic headache, and prevalence. We included population-
based studies in adults and mixed adults/adolescents that estimated CM prevalence
(or provided information to calculate estimates). We deﬁ ned chronicity as a minimum
headache frequency of 10 per month or reported “daily” headache. Where equivalent, 
we combined diagnostic criteria and deﬁ nitions. Findings were qualitatively summa-
rized. RESULTS: Sixteen publications representing 12 unique studies were identiﬁ ed.
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Diagnostic criteria were heterogeneous and included deﬁ nitions based on International 
Classiﬁ cation for Headache Disorders (ICHD) guidelines, Silberstein-Lipton criteria, 
and various investigator-deﬁ ned frequency-based classiﬁ cations. Thus, deﬁ nitions
varied from relatively strict criteria (q15 days/month of migraine) to more liberal cri-
teria (history of migraine and q15 days/month of headache). Prevalence of CM was 
0%-5.1%, with estimates typically in the range of 1.4%-2.2%. Seven studies used 
criteria of history of migraine and q15 days/month of headache (or equivalent), with 
prevalence of 0.9%-5.1%. Three studies used criteria of q15 days/month of migraine
(or equivalent), with prevalence of 0%-0.7%. Two studies stated that the condition 
was transformed migraine or chronic migraine (without speciﬁ c criteria), with preva-
lence of 1.6% and 4.1%. Prevalence varied by WHO region and gender. CONCLU-
SIONS: CM prevalence estimates are inﬂ uenced by speciﬁ c deﬁ nitions employed.
Using the strictest criteria, prevalence was well under 1%; with a less restrictive deﬁ ni-
tion, prevalence was higher, 1%-5%. With these variations, it is difﬁ cult to compare 
results across regions and explore temporal trends. Future studies on CM would 
beneﬁ t from an ICHD consensus diagnosis that is clinically appropriate and opera-
tional in large-scale epidemiological studies.
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PREVALENCE OF ALZHEIMER’S DISEASE AND RELATED DEMENTIA AND
THE CO-EXISTING CONDITIONS IN MANAGED CARE ORGANIZATIONS
Liu M1, Ganguly R2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2GlaxoSmithKline, 
Research Triangle Park, NC, USA
OBJECTIVES: Prevalence data of Alzheimer’s disease and related dementia (ADRD) 
in managed care organizations (MCO) is old and very few data on the prevalence of 
the co-existing conditions. This study aims at investigating the rates and the trend of 
the prevalence of ADRD and the co-existing conditions in MCO over an eleven- year 
period. METHODS: Data are drawn from the Ingenix Impact National Managed Care 
Database (Impact Database). The study time period is 1997–2007. Annual prevalence
of ADRD and two common co-existing conditions (type II diabetes and congestive 
heart failure) are calculated among those aged q50 and those aged q65. Prevalence of 
the co-existing conditions among ADRD patients are compared to the prevalence
among the general population in the same age group. Data extraction and prevalence
calculations are performed in SAS 9.1. RESULTS: From 1997 to 2001, prevalence of 
ADRD increased dramatically among those aged 50 and aged 65. Prevalence of ADRD 
starts to level off during 2005–2007 in both age groups. For the two co-morbid condi-
tions that are investigated, 1) prevalence of diabetes is 2.3 times higher in ADRD 
patients than in the general population, prevalence of congestive heart failure is 5 
times higher; and 2) during 1997–2007, prevalence of both co-morbid conditions 
among ADRD patients are constantly increasing, whereas the prevalence in the general 
population are variant. CONCLUSIONS: In this study, prevalence estimates of ADRD 
are consistent with the literature. The ﬁ nding that the prevalence of ADRD starts to 
level off since 2005 may indicate that for persons under the care of MCO, the under-
diagnose of ADRD may drop to a certain level in recent years. The substantially higher
prevalence of co-morbid conditions among ADRD patients and its constantly increas-
ing trend may pose both challenge and opportunity to MCO managers in their strate-
gies for containing costs.
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RATE OF DISEASE PROGRESSION AMONG PATIENTS WITH 
PARKINSON’S DISEASE IN SINGAPORE
Zhao YJ1, Tan LC2, Seah SH2, Lau PN2, Au WL2, Li SC3, Luo N1, Wee HL1
1National University of Singapore, Singapore, Singapore, 2National Neuroscience Institute, 
Singapore, Singapore, 3University of Newcastle, Callaghan, Australia
OBJECTIVES: Worldwide, data on the long term prognosis of Parkinson’s disease 
(PD) are limited, particularly in South-east Asia. This study was carried out to inves-
tigate the time taken to transit between Hoehn & Yahr (H&Y) stages among patients 
with PD in Singapore. METHODS: Patients were recruited from a tertiary neurosci-
ence clinic in Singapore. Both patients’ clinical and demographic information were
obtained from hospital’s database. Time-to-transition was computed using Kaplan-
Meier analysis. Cox regression analysis was performed to examine the inﬂ uence of 
gender, race, duration of PD and age-at-diagnosis on time-to-transition. RESULTS: A
total of 695 patients (mean age: 65.3, male: 58%) consented to participate in the 
study. Using Kaplan-Meier analysis, the time-to-transition from H&Y stage 1 to 2, 
from 2 to 2.5, from 2.5 to 3 were 22.3, 52.9 and 30.3 months, respectively. Time-to-
transition from stage 3 to 4, and from stage 4 to 5 were 27.4 and 30.0 months, 
respectively. In Cox regression analysis, younger-onset (age at diagnosis  83.6 as refer-
ence group, p  0.006; age at diagnosis  56.1, f p  1.713, p  0.011) and shorter 
PD duration (duration  14.7 as reference group, p  0.002; duration  4.9, f p 
2.188, p  0.001; duration  7.5, f p  1.443, p  0.030) predicted longer time-to-
transition from stage 2 to 2.5. Shorter PD duration (duration  22.8, p  0.021) simi-
larly predicted longer duration from stage 4 to 5. CONCLUSIONS: To the best of 
our knowledge, this is the ﬁ rst study to report on disease progression using time-to-
transition between various H&Y stages. Our ﬁ ndings were similar from current litera-
ture in that younger-onset patients took longer to reach advanced stages. However, 
unlike published literature, disease progression was not slower among female com-
pared to male patients in our study. This could be a real difference or could be due
to different ways of measuring disease progression. The data are thus interesting and 
worth further exploration. These information are also important to clinicians to help
improve patient management.
PND5
CLINICAL CONSEQUENCES OF GENERIC SWITCHES OF ANTI-
EPILEPTIC DRUGS—TRANSFER OF CANADIAN CLAIMS DATABASE
RESULTS TO GERMANY
Bonthapally V1, Gaudig M2
1University of Louisiana at Monroe, Monroe, LA, USA, 2Janssen-Cilag, Neuss, Germany
OBJECTIVES: To assess the proportion of patients with epilepsy switching back to 
branded lamotrigine after generic substitution, to investigate the possible clinical 
consequences of generic substitution in Germany, and to compare the results with 
published research data. German national guidelines recommend not to switch stable
epileptic patients to a generic version of the anti-epileptic drug (AED). METHODS:
Retrospective IMS Disease Analyzer with longitudinal data (January 2005 to July 
2008) was used. An open-cohort design was used to classify patients’ observation into
mutually-exclusive periods of branded versus generic use of lamotrigine. Periods of 
generic use were further stratiﬁ ed into single-generic, multiple-generic use, and switch-
back-cohort. Published results from Québec’s provincial health care-plan (RAMQ) 
from April 1998 to July 2006 were used as comparator. Patients with at least one 
diagnosis for epilepsy (ICD-10: G40.x) and at least one prescription of Lamotrigine 
(ATC-N03A0) were selected. RESULTS: A total of 1,171 patients (674 female
(57.5%), mean age 39.0, SD 17.4) were observed in the German data. Compared to 
the RAMQ database, we found a similar distribution of patients’ demographics, 
periods of brand use and generic switching. In the switch-group, 30.3 % of patients
switched back to branded lamotrigine. There was a statistically signiﬁ cant difference
between brand and generic periods for mean (paired t-test, p  0.0001) and median 
(sign-test, p  0.0001) daily dose. In contrast, the group switching from branded to
generic and back to branded lamotrigine showed no signiﬁ cant difference in the mean 
(p  0.4482) and median daily dose (p  0.7744). CONCLUSIONS: Lamotrigine 
patients in Germany switching from brand to generic lamotrigine experienced similar
clinical consequences of generic substitution, as reported previously, also for other 
AEDs. Given the same characteristics as here, results can be transferred to a different 
population. Therefore, we expect comparable clinical consequences and switch back 
patterns for topiramate generic substitution in Germany.
NEUROLOGICAL DISORDERS – Cost Studies
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COMPARISON OF COSTS FOR INTERFERON BETA 1-A AND
NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
Kozma C1, Dickson M2, Meletiche DM3
1University of South Carolina, West Columbia, SC, USA, 2University of South Carolina, 
Columbia, SC, USA, 3EMD Serono, Inc, Rockland, MA, USA
OBJECTIVES: To compare cost of care for interferon beta (IFNB)-1a subcutaneous 
(SC) and natalizumab in patients with multiple sclerosis (MS). METHODS: In this 
post hoc analysis, eligible patients (18 and 65 years) had an MS diagnosis in a
national managed care database, q1 new medical or prescription claim for IFNB-1a 
SC or natalizumab during the July 1, 2006 to December 31, 2006 selection period,
and were continuously eligible for 12 months before and after the initial disease-
modifying drug (DMD) claim in the selection period. Managed care costs represented
both total and component costs. A propensity score was calculated as the probability 
of being in either treatment group from preperiod variables (eg, age, sex, region). 
Analysis of covariance was used to evaluate total and component costs by treatment 
cohort. RESULTS: A total of 421 patients (IFNB-1a SC  222, natalizumab  199) 
met study criteria. Most patients were women (IFNB-1a SC, 77.9%; natalizumab, 
74.4%), but were older in the natalizumab group (mean [SD] 45.5 [9.7] y vs 42.2 
[10.7] y). DMD use differed by region, and more natalizumab patients were enrolled 
in HMOs (43.2% vs 32.4%). The percentage of patients with no evidence of DMD
use in the preperiod was 26.6% for natalizumab and 63.5% for IFNB-1a SC. Least
square (LS) means differences between IFNB-1a SC and natalizumab for total and 
prescription costs were a function of the number of days of exposure. At the average 
exposure of 290 days, total LS mean cost for IFNB-1a SC and natalizumab were 
$26,433 and $35,980, respectively (P  0.0001). Prescription costs were signiﬁ cantly
higher for natalizumab compared with IFNB-1a SC ($26,775 vs $20,187; P  0.0001). 
Outpatient costs were signiﬁ cantly greater for natalizumab patients ($8640) than for
IFNB-1a SC patients ($4930; P  0.0001). CONCLUSIONS: Patients initiated on 
natalizumab had greater total, prescription, and outpatient costs than did patients 
initiated on IFNB-1a SC.
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RELATION OF HEADACHE FREQUENCY TO HEALTH CARE 
UTILIZATION, WORK PRODUCTIVITY, AND TOTAL COSTS: RESULTS 
FROM THE AMERICAN MIGRAINE PREVALENCE AND PREVENTION 
(AMPP) STUDY
Munakata J1, Serrano D2, Klingman D1, Hazard E1, Rupnow MF3, Tierce J1, Reed M2, 
Stewart WF4, Lipton RB5
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OBJECTIVES: To assess the impact of headache frequency on health care utilization,
medication use, productivity loss, and total costs. METHODS: The American
Migraine Prevalence and Prevention (AMPP) Study is a 5-year, national, longitudinal
